Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
DiabetesontheNet Logo
×

Issue:

Share this article
Share on facebook
Share on twitter
Share on email
Share on print

Efficacy of adjunct liraglutide therapy according to baseline HbA1c, BMI and insulin regimen

Reductions in HbA1c, weight and insulin requirements observed independent of baseline HbA1c, BMI or insulin delivery method. Beta-cell function remains the only clinically relevant parameter to significantly impact the effects of liraglutide, with residual beta-cell function (as measured by C-peptide levels) leading to greater reductions in HbA1c and lower risk of hypoglycaemia.

In the phase 3 ADJUNCT ONE and TWO studies, the glucagon-like peptide-1 receptor agonist liraglutide has previously been shown to improve HbA1c, body weight and insulin requirements when used as an adjunct to insulin therapy in people with type 1 diabetes. The present post hoc analysis of these trials sought to determine whether the benefits were consistent across different levels of baseline HbA1c, BMI and insulin regimens.

Data from a total of 2233 participants were analysed. In general, there was a dose–response relationship between liraglutide (0.6 mg, 1.2 mg and 1.8 mg) and outcomes. At 26 weeks, significant reductions in HbA1c (~3.5 mmol/mol), body weight (~5 kg) and daily insulin requirements (~10%) were observed with the highest dose of liraglutide (1.8 mg) compared with placebo in the two trials.

In both trials, the reductions in HbA1c, body weight and insulin dose were found to be independent of baseline HbA1c (< or ≥69 mmol/mol), BMI (< or ≥27 kg/m2) or insulin regimen (multiple daily injections or insulin pump). There were no significant differences in hypoglycaemia rates between the liraglutide and placebo groups. Thus, the authors conclude that the efficacy and safety of liraglutide does not differ according to baseline HbA1c, BMI or insulin regimen in people with type 1 diabetes.

Beta-cell function remains the only clinically relevant parameter to significantly impact the effects of liraglutide, with residual beta-cell function (as measured by C-peptide levels) leading to greater reductions in HbA1c and lower risk of hypoglycaemia.

Click here to read the study in full.

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
Related content
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
DiabetesontheNet Logo
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.